L1 79Alternative Names: L1-79
Latest Information Update: 08 Nov 2016
At a glance
- Originator Yamo Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Autistic disorder
Most Recent Events
- 01 Oct 2016 Phase-II clinical trials in Autistic disorder (In adolescents, In adults) in USA (PO)